Avidity Partners Increases Stake in Enliven Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: Fool
- Increased Holdings: Avidity Partners Management acquired an additional 259,700 shares of Enliven Therapeutics in Q1 2026, valued at approximately $7.19 million, indicating strong confidence in the company's future potential.
- Market Capitalization Growth: As of March 31, 2026, Enliven's market capitalization reached $2.65 billion, with its stock price increasing by 120% over the past year, significantly outperforming the S&P 500's 26% rise, reflecting positive market expectations for its products.
- R&D Progress: Enliven is advancing its clinical trials for small molecule kinase inhibitors, particularly ELVN-001 for chronic myeloid leukemia, with new clinical data expected by mid-2026, further bolstering investor confidence.
- Strong Financial Position: As of Q1 2026, Enliven held approximately $452 million in cash and marketable securities, which is projected to fund operations into the first half of 2029, demonstrating a solid financial foundation in the clinical-stage biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.650
Low
35.00
Averages
40.67
High
48.00
Current: 40.650
Low
35.00
Averages
40.67
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surge in Options Trading Volume for Apple and Coinbase
- Apple Options Volume: Apple Inc (AAPL) saw options trading volume of 1.1 million contracts, equivalent to approximately 113 million shares, representing a 225.4% increase over its average daily trading volume of 50.2 million shares in the past month, indicating strong market interest in its future performance.
- High Strike Activity: Notably, the $315 strike call option expiring on May 29, 2026, recorded a trading volume of 143,582 contracts today, representing about 14.4 million underlying shares, suggesting a significant bullish sentiment among investors regarding Apple's stock price.
- Coinbase Options Dynamics: Coinbase Global Inc (COIN) experienced options trading volume of 204,154 contracts, translating to approximately 20.4 million shares, which is 213.4% of its average daily trading volume of 9.6 million shares over the past month, reflecting positive market sentiment towards its future trajectory.
- Bullish Call Options: The $190 strike call option expiring on May 29, 2026, saw a trading volume of 13,657 contracts today, equivalent to about 1.4 million underlying shares, indicating investor optimism about Coinbase's future performance.
See More
Avidity Partners Increases Stake in Enliven Therapeutics
- Increased Holdings: Avidity Partners Management acquired an additional 259,700 shares of Enliven Therapeutics in Q1 2026, valued at approximately $7.19 million, indicating strong confidence in the company's future potential.
- Market Capitalization Growth: As of March 31, 2026, Enliven's market capitalization reached $2.65 billion, with its stock price increasing by 120% over the past year, significantly outperforming the S&P 500's 26% rise, reflecting positive market expectations for its products.
- R&D Progress: Enliven is advancing its clinical trials for small molecule kinase inhibitors, particularly ELVN-001 for chronic myeloid leukemia, with new clinical data expected by mid-2026, further bolstering investor confidence.
- Strong Financial Position: As of Q1 2026, Enliven held approximately $452 million in cash and marketable securities, which is projected to fund operations into the first half of 2029, demonstrating a solid financial foundation in the clinical-stage biopharmaceutical sector.
See More
Enliven's ELVN-001 Shows Promising Trial Results and Analyst Support
- Trial Results: The ENABLE trial results as of December 22, 2025, indicate that ELVN-001 shows promising efficacy and a favorable safety profile in heavily pretreated chronic myeloid leukemia patients, with 76% of the 141 enrolled patients still on treatment and a median treatment duration of 31.7 weeks, demonstrating sustained anti-CML activity.
- Future Trial Plans: Enliven is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026, reflecting the company's confidence in the drug's potential and its strategic importance in the market.
- Analyst Rating Upgrade: Guggenheim Securities initiated coverage of Enliven with a ‘Buy’ rating and an $80 price target, viewing ELVN-001 as a potential best-in-class oral therapy for CML, while noting that the current valuation does not fully capture its commercial opportunity.
- Positive Market Reaction: Following the announcement of positive data presentation at an upcoming conference, Enliven's stock surged 7%, indicating strong market optimism regarding its development progress, with the stock having more than doubled over the past 12 months, reflecting investor confidence in future growth.
See More
Enliven Therapeutics Reports Positive Data on ELVN-001 for CML
- Clinical Trial Progress: In the ENABLE clinical trial, ELVN-001 demonstrated a favorable safety and tolerability profile in 141 patients with a median treatment duration of approximately 32 weeks, indicating its potential application in chronic myeloid leukemia (CML).
- Efficacy Data Update: In the 80 mg QD Phase 1b cohort, the cumulative major molecular response (MMR) rate was 47%, with 38% of patients achieving MMR by 24 weeks, showcasing ELVN-001's robust anti-CML activity in heavily pretreated patients.
- Upcoming Conference Data: Enliven is set to present updated data at the 2026 European Hematology Association Congress, which is expected to further enhance the clinical prospects of ELVN-001, particularly in patients resistant to existing tyrosine kinase inhibitors (TKIs).
- Strategic Implications: ELVN-001's distinct binding mode and complementary mechanism to allosteric inhibitors may position it as a best-in-class option for CML treatment, further solidifying Enliven's market position in the biopharmaceutical sector.
See More
Enliven Therapeutics Announces Updated Clinical Data for ELVN-001
- Clinical Trial Progress: As of December 22, 2025, 141 patients with chronic myeloid leukemia (CML) were enrolled in the Phase 1 trial of ELVN-001, with 76% remaining on treatment for an average of 31.7 weeks, demonstrating favorable safety and tolerability in heavily pretreated patients.
- Efficacy Data Update: In the initial 80 mg QD Phase 1b cohort, 47% of patients achieved major molecular response (MMR), while in the randomized 60 mg and 120 mg QD cohorts, 69% achieved MMR, indicating ELVN-001's potential in treating refractory CML patients.
- Safety Analysis: ELVN-001 exhibited a favorable safety profile, with less than 10% of patients experiencing dose reductions due to treatment-emergent adverse events, and only 6.4% discontinuing treatment due to adverse events, reinforcing its advantages as a selective kinase inhibitor.
- Future Outlook: Enliven plans to present additional data at the European Hematology Association Congress on June 11, 2026, highlighting ELVN-001's prospects as a potential best-in-class therapy, particularly in targeting the BCR::ABL1 gene fusion in CML treatment.
See More
Helen Collins Sells 40,000 Shares of Enliven Therapeutics
- Transaction Overview: Helen Louise Collins exercised and sold 40,000 shares of Common Stock between March 9-10, 2026, generating approximately $1.20 million at a weighted average price of $30.07 per share, reducing her direct holdings by 61.54% from 65,000 to 25,000 shares.
- Market Reaction Analysis: Following Collins' sale, Enliven Therapeutics' stock closed at $30.24 on March 10, 2026, indicating positive market sentiment towards the company's future potential, despite Collins selling at a lower price than the subsequent market value.
- Clinical Progress and Competition: Enliven Therapeutics focuses on developing small-molecule therapies for cancer, with its CML candidate ELVN-001 showing a 47% major molecular response rate at 24 weeks, although Merck's acquisition of Terns Pharmaceuticals may spark interest in acquiring Enliven.
- Investor Caution: Despite Enliven Therapeutics' potential in the biotech sector, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to carefully consider market dynamics before making investment decisions.
See More
Surge in Options Trading Volume for Apple and Coinbase
- Apple Options Volume: Apple Inc (AAPL) saw options trading volume of 1.1 million contracts, equivalent to approximately 113 million shares, representing a 225.4% increase over its average daily trading volume of 50.2 million shares in the past month, indicating strong market interest in its future performance.
- High Strike Activity: Notably, the $315 strike call option expiring on May 29, 2026, recorded a trading volume of 143,582 contracts today, representing about 14.4 million underlying shares, suggesting a significant bullish sentiment among investors regarding Apple's stock price.
- Coinbase Options Dynamics: Coinbase Global Inc (COIN) experienced options trading volume of 204,154 contracts, translating to approximately 20.4 million shares, which is 213.4% of its average daily trading volume of 9.6 million shares over the past month, reflecting positive market sentiment towards its future trajectory.
- Bullish Call Options: The $190 strike call option expiring on May 29, 2026, saw a trading volume of 13,657 contracts today, equivalent to about 1.4 million underlying shares, indicating investor optimism about Coinbase's future performance.
See More
Avidity Partners Increases Stake in Enliven Therapeutics
- Increased Holdings: Avidity Partners Management acquired an additional 259,700 shares of Enliven Therapeutics in Q1 2026, valued at approximately $7.19 million, indicating strong confidence in the company's future potential.
- Market Capitalization Growth: As of March 31, 2026, Enliven's market capitalization reached $2.65 billion, with its stock price increasing by 120% over the past year, significantly outperforming the S&P 500's 26% rise, reflecting positive market expectations for its products.
- R&D Progress: Enliven is advancing its clinical trials for small molecule kinase inhibitors, particularly ELVN-001 for chronic myeloid leukemia, with new clinical data expected by mid-2026, further bolstering investor confidence.
- Strong Financial Position: As of Q1 2026, Enliven held approximately $452 million in cash and marketable securities, which is projected to fund operations into the first half of 2029, demonstrating a solid financial foundation in the clinical-stage biopharmaceutical sector.
See More
Enliven's ELVN-001 Shows Promising Trial Results and Analyst Support
- Trial Results: The ENABLE trial results as of December 22, 2025, indicate that ELVN-001 shows promising efficacy and a favorable safety profile in heavily pretreated chronic myeloid leukemia patients, with 76% of the 141 enrolled patients still on treatment and a median treatment duration of 31.7 weeks, demonstrating sustained anti-CML activity.
- Future Trial Plans: Enliven is preparing to advance ELVN-001 into a pivotal late-stage trial in the second half of 2026, reflecting the company's confidence in the drug's potential and its strategic importance in the market.
- Analyst Rating Upgrade: Guggenheim Securities initiated coverage of Enliven with a ‘Buy’ rating and an $80 price target, viewing ELVN-001 as a potential best-in-class oral therapy for CML, while noting that the current valuation does not fully capture its commercial opportunity.
- Positive Market Reaction: Following the announcement of positive data presentation at an upcoming conference, Enliven's stock surged 7%, indicating strong market optimism regarding its development progress, with the stock having more than doubled over the past 12 months, reflecting investor confidence in future growth.
See More
Enliven Therapeutics Reports Positive Data on ELVN-001 for CML
- Clinical Trial Progress: In the ENABLE clinical trial, ELVN-001 demonstrated a favorable safety and tolerability profile in 141 patients with a median treatment duration of approximately 32 weeks, indicating its potential application in chronic myeloid leukemia (CML).
- Efficacy Data Update: In the 80 mg QD Phase 1b cohort, the cumulative major molecular response (MMR) rate was 47%, with 38% of patients achieving MMR by 24 weeks, showcasing ELVN-001's robust anti-CML activity in heavily pretreated patients.
- Upcoming Conference Data: Enliven is set to present updated data at the 2026 European Hematology Association Congress, which is expected to further enhance the clinical prospects of ELVN-001, particularly in patients resistant to existing tyrosine kinase inhibitors (TKIs).
- Strategic Implications: ELVN-001's distinct binding mode and complementary mechanism to allosteric inhibitors may position it as a best-in-class option for CML treatment, further solidifying Enliven's market position in the biopharmaceutical sector.
See More
Enliven Therapeutics Announces Updated Clinical Data for ELVN-001
- Clinical Trial Progress: As of December 22, 2025, 141 patients with chronic myeloid leukemia (CML) were enrolled in the Phase 1 trial of ELVN-001, with 76% remaining on treatment for an average of 31.7 weeks, demonstrating favorable safety and tolerability in heavily pretreated patients.
- Efficacy Data Update: In the initial 80 mg QD Phase 1b cohort, 47% of patients achieved major molecular response (MMR), while in the randomized 60 mg and 120 mg QD cohorts, 69% achieved MMR, indicating ELVN-001's potential in treating refractory CML patients.
- Safety Analysis: ELVN-001 exhibited a favorable safety profile, with less than 10% of patients experiencing dose reductions due to treatment-emergent adverse events, and only 6.4% discontinuing treatment due to adverse events, reinforcing its advantages as a selective kinase inhibitor.
- Future Outlook: Enliven plans to present additional data at the European Hematology Association Congress on June 11, 2026, highlighting ELVN-001's prospects as a potential best-in-class therapy, particularly in targeting the BCR::ABL1 gene fusion in CML treatment.
See More
Helen Collins Sells 40,000 Shares of Enliven Therapeutics
- Transaction Overview: Helen Louise Collins exercised and sold 40,000 shares of Common Stock between March 9-10, 2026, generating approximately $1.20 million at a weighted average price of $30.07 per share, reducing her direct holdings by 61.54% from 65,000 to 25,000 shares.
- Market Reaction Analysis: Following Collins' sale, Enliven Therapeutics' stock closed at $30.24 on March 10, 2026, indicating positive market sentiment towards the company's future potential, despite Collins selling at a lower price than the subsequent market value.
- Clinical Progress and Competition: Enliven Therapeutics focuses on developing small-molecule therapies for cancer, with its CML candidate ELVN-001 showing a 47% major molecular response rate at 24 weeks, although Merck's acquisition of Terns Pharmaceuticals may spark interest in acquiring Enliven.
- Investor Caution: Despite Enliven Therapeutics' potential in the biotech sector, the Motley Fool Stock Advisor analyst team did not include it in their current list of top investment stocks, advising investors to carefully consider market dynamics before making investment decisions.
See More
